Prolific Machines secures investment and announces partnerships

Prolific Machines has announced a new investment and strategic partnerships to scale its optogenetics platform for biomanufacturing. The funding, led by Atoms & Bits and Nant Capital, is intended to support team growth, technological development, and the scaling of programs involving biologics, biosimilars, and viral vectors. The company also plans to fund early-stage research into tissue and organ fabrication.

In addition to the investment, Prolific Machines has entered into a partnership with Zylidac Bio, a biologics contract development and manufacturing organization (CDMO) based in the San Francisco Bay Area. This collaboration aims to scale the production of Optogentics-enabled cell lines for clinical and Good Manufacturing Practice (GMP) manufacturing.

Furthermore, a strategic collaboration has been established with NantWorks to apply Prolific’s platform across various biologic programs within the NantWorks health and life sciences portfolio.